Rebamipide: a gastrointestinal protective drug with pleiotropic activities

References

• Uchida M, Tabusa F, Komatsu M et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid related compounds. Chem. Pharm. Bull.33(9), 3775–3786 (1985).
   PubMed Web of Science ®Google Scholar
• Uchida M, Tabusa F, Komatsu M et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. synthesis and antiulcer activity of the metabolites of 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid. Chem. Pharm. Bull.34(9), 4821–4824 (1986).
   PubMed Web of Science ®Google Scholar
• Uchida M, Tabusa F, Komatsu M et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. synthesis and antiulcer activity of optically active a-amino acid derivatives of 2(1H)-quinolinone and oxindole. Chem. Pharm. Bull.35(2), 853–856 (1987).
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Ishiyama H, Imaizumi T et al. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jpn. J. Pharmacol.49(4), 441–448 (1989).
   PubMedGoogle Scholar
• Iijima K, Ichikawa T, Okada S et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig. Dis. Sci.54(7), 1500–1507 (2009).
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur. J. Pharmacol.142(1), 23–29 (1987).
   PubMed Web of Science ®Google Scholar
• Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig. Dis. Sci.38(8), 1441–1449 (1993).
   PubMed Web of Science ®Google Scholar
• Suetsugu H, Ishihara S, Moriyama N et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J. Lab. Clin. Med.136(1), 50–57 (2000).
   PubMed Web of Science ®Google Scholar
• Sun WH, Tsuji S, Tsujii M et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J. Pharmacol. Exp. Ther.295(2), 447–452 (2000).
   PubMed Web of Science ®Google Scholar
• Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung42(12), 1462–1466 (1992).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung43(3), 363–366 (1993).
   PubMed Web of Science ®Google Scholar
• Naito Y, Yoshikawa T, Tanigawa T et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic. Biol. Med.18(1), 117–123 (1995).
   PubMed Web of Science ®Google Scholar
• Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic. Res.38(5), 487–494 (2004).
   PubMed Web of Science ®Google Scholar
• Ogino K, Hobara T, Ishiyama H et al. Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats. Eur. J. Pharmacol.212(1), 9–13 (1992).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Miura S, Mori M et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut35(10), 1375–1378 (1994).
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-κB and MAPK signaling pathway. Dig. Dis. Sci.46(10), 2277–2284 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig. Dis. Sci.41(6), 1139–1144 (1996).
   PubMed Web of Science ®Google Scholar
• Murakami K, Okajima K, Uchiba M et al. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig. Dis. Sci.42(2), 319–325 (1997).
   PubMed Web of Science ®Google Scholar
• Naito Y, Kuroda M, Mizushima K et al. Transcriptome analysis for cytoprotective actions of rebamipide against indomethacin-induced gastric mucosal injury in rats. J. Clin. Biochem. Nutr.41(3), 202–210 (2007).
   PubMed Web of Science ®Google Scholar
• Kinjo N, Kawanaka H, Akahoshi T et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am. J. Physiol. Gastrointest. Liver Physiol.295(5), G1016–1024 (2008).
   PubMed Web of Science ®Google Scholar
• Nishizawa T, Suzuki H, Nakagawa I et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion79(4), 259–262 (2009).
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Sekino H, Matsuoka O et al. Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers. Clin. Drug Investig.23(12), 771–779 (2003).
   PubMed Web of Science ®Google Scholar
• Shioya Y, Shimizu T. High-performance liquid chromatographic procedure for the determination of a new anti-gastric ulcer agent, 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid, in human plasma and urine. J. Chromatogr.434(1), 283–287 (1988).
   PubMed Web of Science ®Google Scholar
• Koyama N, Sasabe H, Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica32(7), 573–586 (2002).
   PubMed Web of Science ®Google Scholar
• Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf.29(9), 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Hansten PD. Aliment drug interactions with antisecretory agents. Pharmacol. Ther.5(Suppl. 1), 121–128 (1991).
   Web of Science ®Google Scholar
• Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig. Dis. Sci.43(9 Suppl.), 5S–13S (1998).
   PubMed Web of Science ®Google Scholar
• Arakawa T, Higuchi K, Fujiwara Y et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig. Dis. Sci.50(Suppl. 1), S3–S11 (2005).
   PubMed Web of Science ®Google Scholar
• Turner J. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol.9(11), 799–809 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J. Pharmacol. Sci.106(3), 469–477 (2008).
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Oshima T, Tomita T et al. Oxidative stress induces gastric epithelial permeability through claudin-3. Biochem. Biophys. Res. Commun.376(1), 154–157 (2008).
   PubMed Web of Science ®Google Scholar
• Laharie D, Menard S, Asencio C et al. Effect of rebamipide on the colonic barrier in interleukin-10-deficient mice. Dig. Dis. Sci.52(1), 84–92 (2007)
   PubMed Web of Science ®Google Scholar
• Terano A, Arakawa T, Sugiyama T et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J. Gastroenterol.42(8), 690–693 (2007).
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Aihara E, Takasuka H, Takahashi K, Takeuchi K. Antral ulcers induced by alendronate, a nitrogen-containing biphophonate, in rat stomachs – prophylactic effect of rebamipide. J. Physiol. Pharmacol.60(3), 85–93 (2009).
   PubMed Web of Science ®Google Scholar
• Aihara E, Hayashi S, Amagase K, Kato S, Takeuchi K. Prophylactic effect of rebamipide against the irritative and healing impairment actions of alendronate in rat stomachs. Inflammopharmacology15(5), 196–202 (2007).
   PubMedGoogle Scholar
• Yoshikawa T, Naito Y, Nakamura S et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneimittelforschung43(12), 1327–1330 (1993).
   PubMed Web of Science ®Google Scholar
• Naito Y, Kuroda M, Mizushima K et al. Transcriptome analysis for cytoprotective actions of rebamipide against indomethacin-induced gastric mucosal injury in rats. J. Clin. Biochem. Nutr.41(3), 202–210 (2007).
   PubMed Web of Science ®Google Scholar
• Iwai A, Iwashita E. Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig. Dis. Sci.43(9 Suppl.), 143S–147S (1998).
   Google Scholar
• Kishimoto S, Haruma K, Tari A et al. Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig. Dis. Sci.45(8), 1608–1616 (2000).
   PubMed Web of Science ®Google Scholar
• Okayama M, Tsubouchi R, Nishio H, Kato S, Takeuchi K. Protective effect of intra-rectal administration of rebamipide on dextran sulfate sodium-induced rat colitis. Digestion70(4), 240–249 (2004).
   PubMed Web of Science ®Google Scholar
• Nakashima T, Maeda T, Nagamoto H et al. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats. Dig. Dis. Sci.50(Suppl. 1), S124–S131 (2005).
   Web of Science ®Google Scholar
• Murai R, Kanbe T, Mukoyama T et al. Effect of rectal administration of rebamipide on dextran sulfate sodium-induced colitis: role of hepatocyte growth factor. Inflamm. Res.56(6), 240–245 (2007).
   PubMed Web of Science ®Google Scholar
• Tarnawski A, Pai R, Chiou SK, Chai J, Chu EC. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem. Biophys. Res. Commun.334(1), 207–212 (2005).
   PubMed Web of Science ®Google Scholar
• Tanigawa T, Pai R, Arakawa T, Tarnawski AS. Rebamipide inhibits gastric cancer cell growth. Dig. Dis. Sci.52(1), 240–247 (2007).
   PubMed Web of Science ®Google Scholar
• Higuchi K, Fujiwara Y, Tominaga K et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment. Pharmacol. Ther.17(1), 111–117 (2003).
   PubMedGoogle Scholar
• Terano A, Arakawa T, Sugiyama T et al. A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide. J. Gastroenterol. Hepatol.21(1 Pt 1), 103–109 (2006).
   PubMed Web of Science ®Google Scholar
• Kato T, Araki H, Onogi F et al. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection – a randomized controlled study. J. Gastroenterol.45(3), 285–290 (2009).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Zinsmeister AR, Schleck CD et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology102(4 Pt 1), 1259–1268 (1992).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Riff DS, Schwartz H, Marcuard SP. Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment. Pharmacol. Ther.15(10), 1603–1611 (2001).
   PubMed Web of Science ®Google Scholar
• Miwa H, Osada T, Nagahara A et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J. Gastroenterol. Hepatol.21(12), 1826–1831 (2006).
   PubMed Web of Science ®Google Scholar
• Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig. Dis. Sci.53(11), 2896–2903 (2008).
   PubMed Web of Science ®Google Scholar
• Du Y, Li Z, Zhan X et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig. Dis. Sci.53(11), 2886–2895 (2008).
   PubMed Web of Science ®Google Scholar
• Naito Y, Yoshikawa T, Yoshida N, Kondo M. Role of oxygen radical and lipid peroxidation in indomethacin-induced gastric mucosal injury. Dig. Dis. Sci.43(9 Suppl.), 30S–34S (1998).
   Web of Science ®Google Scholar
• Naito Y, Iinuma S, Yagi N et al. Prevention of Indomethacin-induced gastric mucosal injury in Helicobacter pylori-negative healthy volunteers: a comparison study rebamipide vs famotidine. J. Clin. Biochem. Nutr.43(1), 34–40 (2008).
   PubMed Web of Science ®Google Scholar
• Kim HK, Kim JI, Kim JK et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig. Dis. Sci.52(8), 1776–1782 (2007).
   PubMed Web of Science ®Google Scholar
• Yamao J, Kikuchi E, Matsumoto M et al. Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE – famotidine or rebamipide in comparison by endoscopy). J. Gastroenterol.41(12), 1178–1185 (2006).
   PubMed Web of Science ®Google Scholar
• Park SH, Cho CS, Lee OY et al. Comparison of prevention of NSAID-Induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial – STORM STUDY. J. Clin. Biochem. Nutr.40(2), 148–155 (2007).
   PubMed Web of Science ®Google Scholar
• Ono S, Kato M, Imai A et al. Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J. Clin. Biochem. Nutr.45(2), 248–253 (2009).
   PubMed Web of Science ®Google Scholar
• Niwa Y, Nakamura M, Ohmiya N et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J. Gastroenterol.43(4), 270–276 (2008).
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, Ogawa Y, Kanatsu K et al. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J. Gastroenterol. Hepatol.16(10), 1112–1119 (2001).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Sugimori S, Kameda N et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin. Gastroenterol. Hepatol.6(11), 1279–1282 (2008).
   PubMed Web of Science ®Google Scholar
• Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL. Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am. J. Gastroenterol.95(7), 1838–1839 (2000).
   PubMed Web of Science ®Google Scholar
• Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig. Dis. Sci.50(12), 2323–2329 (2005).
   PubMed Web of Science ®Google Scholar
• Miyata M, Kasugai K, Ishikawa T et al. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig. Dis. Sci.50(Suppl. 1), S119–S123 (2005).
   Web of Science ®Google Scholar
• Furuta R, Kusugami K, Goto H. [Enema therapy for ulcerative colitis patients]. Nippon Rinsho63(5), 845–849 (2005).
   PubMedGoogle Scholar
• Arakawa T, Kobayashi K. Quality of ulcer healing – a new concept to rank healed peptic ulcers. Gastroenterol. Jpn.28(Suppl. 5), 158–162 (1993).
   PubMedGoogle Scholar